280 related articles for article (PubMed ID: 32244049)
1. Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy.
Deligiorgi MV; Siasos G; Vergadis C; Trafalis DT
Int Immunopharmacol; 2020 Jun; 83():106427. PubMed ID: 32244049
[TBL] [Abstract][Full Text] [Related]
2. AVP deficiency (central diabetes insipidus) following immunization with anti-COVID-19 BNT162b2 Comirnaty vaccine in adolescents: A case report.
Partenope C; Pedranzini Q; Petri A; Rabbone I; Prodam F; Bellone S
Front Endocrinol (Lausanne); 2023; 14():1166953. PubMed ID: 37143723
[TBL] [Abstract][Full Text] [Related]
3. Anti-PD-1 treatment-induced immediate central diabetes insipidus: a case report.
Yu M; Liu L; Shi P; Zhou H; Qian S; Chen K
Immunotherapy; 2021 Oct; 13(15):1255-1260. PubMed ID: 34424037
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of anti-rabphilin-3A antibodies for diagnosing central diabetes insipidus in the third trimester of pregnancy.
Sakurai K; Yamashita R; Niituma S; Iwama S; Sugimura Y; Arihara Z; Takahashi K
Endocr J; 2017 Jun; 64(6):645-650. PubMed ID: 28420857
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of central diabetes insipidus using a vasopressin radioimmunoassay during hypertonic saline infusion.
Takagi H; Hagiwara D; Handa T; Sugiyama M; Onoue T; Tsunekawa T; Ito Y; Iwama S; Goto M; Suga H; Banno R; Takahashi K; Matsui S; Arima H
Endocr J; 2020 Mar; 67(3):267-274. PubMed ID: 31748430
[TBL] [Abstract][Full Text] [Related]
6. Central diabetes insipidus with anti-rabphilin-3A antibody positivity causing hypovolemic shock after resection of tumorous lesions in the pelvic cavity.
Ohashi A; Takeda Y; Watada M; Ihara F; Oshita T; Iwata N; Fujisawa H; Suzuki A; Sugimura Y; Maeda Y
CEN Case Rep; 2023 Aug; 12(3):297-303. PubMed ID: 36574196
[TBL] [Abstract][Full Text] [Related]
7. Diabetes insipidus: A rare endocrine complication of immune check point inhibitors: A case report and literature review.
Angelousi A; Papalexis P; Karampela A; Marra M; Misthos D; Ziogas D; Gogas H
Exp Ther Med; 2023 Jan; 25(1):10. PubMed ID: 36561623
[TBL] [Abstract][Full Text] [Related]
8. Central Diabetes Insipidus in the Background of Lithium Use: Consider Central Causes Despite Nephrogenic as the Most Common.
Li JJ; Tan S; Kawashita T; Tagle CA; Farmand F
Am J Case Rep; 2023 Jan; 24():e939034. PubMed ID: 36683312
[TBL] [Abstract][Full Text] [Related]
9. Idiopathic central diabetes insipidus in an extreme premature infant: A case report.
Biset A; Claris O
Arch Pediatr; 2018 Nov; 25(8):480-484. PubMed ID: 30361085
[TBL] [Abstract][Full Text] [Related]
10. Severe hyperosmolarity and hypernatremia in an adipsic young woman.
Latcha S; Lubetzky M; Weinstein AM
Clin Nephrol; 2011 Nov; 76(5):407-11. PubMed ID: 22000562
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and Management of Central Diabetes Insipidus in Adults.
Tomkins M; Lawless S; Martin-Grace J; Sherlock M; Thompson CJ
J Clin Endocrinol Metab; 2022 Sep; 107(10):2701-2715. PubMed ID: 35771962
[TBL] [Abstract][Full Text] [Related]
12. Central Diabetes Insipidus in Infancy With or Without Hypothalamic Adipsic Hypernatremia Syndrome: Early Identification and Outcome.
Djermane A; Elmaleh M; Simon D; Poidvin A; Carel JC; Léger J
J Clin Endocrinol Metab; 2016 Feb; 101(2):635-43. PubMed ID: 26588450
[TBL] [Abstract][Full Text] [Related]
13. Central diabetes insipidus: alert for dehydration in very low birth weight infants during the neonatal period. A case report.
Ferlin ML; Sales DS; Celini FP; Martinelli Junior CE
Sao Paulo Med J; 2015 Feb; 133(1):60-3. PubMed ID: 25271879
[TBL] [Abstract][Full Text] [Related]
14. Profound hypernatremia due to central diabetes insipidus.
Vaqar A; Rafiq A; Javaid KH; Parveen R; Sadaf R
J Coll Physicians Surg Pak; 2012 Jun; 22(6):409-11. PubMed ID: 22630107
[TBL] [Abstract][Full Text] [Related]
15. Central diabetes insipidus: beware of Langerhans cell histiocytosis!
Brys ADH; Vermeersch S; Forsyth R; Velkeniers B; Bravenboer B
Neth J Med; 2018 Dec; 76(10):445-449. PubMed ID: 30569891
[TBL] [Abstract][Full Text] [Related]
16. Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces.
Deligiorgi MV; Liapi C; Trafalis DT
Expert Opin Biol Ther; 2021 Aug; 21(8):1097-1120. PubMed ID: 33393372
[TBL] [Abstract][Full Text] [Related]
17. Autoimmune diabetes insipidus.
Scherbaum WA
Handb Clin Neurol; 2021; 181():193-204. PubMed ID: 34238458
[TBL] [Abstract][Full Text] [Related]
18. Hyperuricemia as a clue for central diabetes insipidus (lack of V1 effect) in the differential diagnosis of polydipsia.
Decaux G; Prospert F; Namias B; Soupart A
Am J Med; 1997 Nov; 103(5):376-82. PubMed ID: 9375705
[TBL] [Abstract][Full Text] [Related]
19. Central Diabetes Insipidus Due to IgG4-related Hypophysitis That Required over One Year to Reach the Final Diagnosis Due to Symptoms Being Masked by Sialadenitis.
Iwamoto Y; Mori S; Tatsumi F; Sugisaki T; Dan K; Katakura Y; Kimura T; Shimoda M; Nakanishi S; Mune T; Kaneto H
Intern Med; 2022 Dec; 61(23):3541-3545. PubMed ID: 35569983
[TBL] [Abstract][Full Text] [Related]
20. Management of Central Diabetes Insipidus in Disabled Children with Diluted Oral Desmopressin Lyophilisate Formulation Administered Through Nasogastric Tube: A Retrospective Case Series.
Korkmaz HA; Arya VB; Gönüllü A; Coşkunol F; Ozkan B
Paediatr Drugs; 2023 Sep; 25(5):595-601. PubMed ID: 37326929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
